We have been present in the North American region, which includes the US and Canada, since the mid-1990s. It is our largest business, with revenue in FY’22 reaching a historic milestone of $1 billion, and FY’25 closing at approximately $1.7 billion. Our portfolio spans over 230 products across the retail, institutional, and over-the-counter (OTC) segments.
Our pipeline includes several first-to-market drugs and complex products, including drug-device combinations, peptides, and long-acting injectables.
In September 2022, we launched Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules, approved by the U.S. Food and Drug Administration (USFDA). With this volume-limited launch, we became eligible for first-to-market, 180-day generic drug exclusivity for Dr. Reddy’s Lenalidomide Capsules in the 2.5 mg and 20 mg strengths.
Our growth in North America in FY’24 was largely driven by increased volumes in the base business, including Lenalidomide, as well as revenue from new product launches during the year. With patients at the center of everything we do, in December 2023 we entered into an exclusive collaboration with Coya Therapeutics, Inc. for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Read more about this here.
We acquired MenoLabs®, a leading portfolio in women's health and dietary supplements. We collaborated with Mark Cuban Cost Plus Drug Company to improve access to essential medications for patients with Wilson disease. We launched 20 new products, including Treprostinil Injection and Regadenoson Injection in the U.S., as well as products acquired from Mayne Pharma. We also filed 17 new Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (USFDA).
For selected drugs in our portfolio, we offer patient support services. We also partner with specialty pharmacies to unlock the potential of our complex and injectable generics in the growing specialty drug segment. One of the most recent ones is patient support services for Dr. Reddy’s Sapropterin Dihydrochloride. The services include a patient hub, co-pay assistance, benefits/reimbursement liaison, and nutrition and nursing support.
In addition, we have launched our own digital marketplace for the institutional segment DrReddysDirect.com.
Dr. Reddy’s has had a presence in Europe since 2002, when we completed our first overseas acquisition: BMS Laboratories and its subsidiary, Meridian Healthcare in the United Kingdom. Today, we have a presence in multiple European countries through a broad portfolio of generic medicines, biosimilars, and OTC products across multiple therapeutic areas both on our own and via partners. Our operations span both hospital and retail channels, enabling us to address diverse healthcare needs across the region. Headquartered in Basel, Switzerland, we continue to strengthen our footprint through a patient-centric approach and a commitment to delivering sustainable value to all our stakeholders.
Our generics portfolio plays an important role in improving access to high-quality and affordable medicines across Europe We continue to strengthen our portfolio through the introduction of both newly off-patent medicines and established therapies, while expanding their availability across key European markets. Recent notable launches include Rivaroxaban, Nintedanib, Dapagliflozin, Pazopanib, and Albumin-bound Paclitaxel, reflecting our focus on therapies in areas such as respiratory diseases, oncology, and chronic disease management amongst many others.
In Germany, we supply medicinal products through two subsidiaries: betapharm Arzneimittel GmbH and Nimbus Health GmbH (Nimbus Health). While betapharm is our established brand for generics and OTC medicines, Nimbus Health GmbH is a Germany-based, licensed pharmaceutical wholesaler specialised in cannabinoid-based medicinal products. The company supplies pharmacies with a portfolio of medical cannabis flowers, extracts, and selected medical accessories. * Product availability may vary by country. Not all products are currently available in all European markets.
